Company: OROX BioSciences Inc.
Job title: Chief Executive Officer
Inhalable Bifunctional sEH/COX-2 Inhibitors for Treatment of Asthma 1:30 pm
Developing inhalable bifunctional sEH/COX-2 small molecule inhibitors with novel mechanisms of action to treat Asthma Asthma affects over 300 million people worldwide and up to 55% of these patients experience recurrent episodes of bronchospasm despite long-acting beta-agonists plus high-dose inhaled or oral corticosteroids Chronic use of corticosteroids can lead to immune suppression, CVD risk, glaucoma,…Read more
day: Conference Day 2